PL1809293T3 - Formulacja w postaci aerozolu do inhalacji 5 beta – agonistów - Google Patents

Formulacja w postaci aerozolu do inhalacji 5 beta – agonistów

Info

Publication number: PL1809293T3
Authority: PL; Poland
Prior art keywords: inhalation; aerosol formulation; beta agonists; agonists; beta
Prior art date: 2004-05-14

Application number

PL05747843.0T

Other languages

English (en)

Inventor

Michael Aven

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-05-14

Filing date

2005-05-10

Publication date

2016-09-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34979667&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1809293(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-05-10 Application filed filed Critical

2016-09-30 Publication of PL1809293T3 publication Critical patent/PL1809293T3/pl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/04—Amoebicides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pulmonology (AREA)
Epidemiology (AREA)
Immunology (AREA)
Dispersion Chemistry (AREA)
Dermatology (AREA)
Tropical Medicine & Parasitology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

PL05747843.0T 2004-05-14 2005-05-10 Formulacja w postaci aerozolu do inhalacji 5 beta – agonistów PL1809293T3 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE102004024452A DE102004024452A1 (de)	2004-05-14	2004-05-14	Aerosolformulierung für die Inhalation von Betaagonisten

Publications (1)

Publication Number	Publication Date
PL1809293T3 true PL1809293T3 (pl)	2016-09-30

Family

ID=34979667

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL05747843.0T PL1809293T3 (pl)	2004-05-14	2005-05-10	Formulacja w postaci aerozolu do inhalacji 5 beta – agonistów

Country Status (26)

Country	Link
EP (1)	EP1809293B1 (pl)
JP (1)	JP4620730B2 (pl)
KR (1)	KR101288791B1 (pl)
CN (1)	CN101056640A (pl)
AR (1)	AR049096A1 (pl)
AU (1)	AU2005244414B2 (pl)
BR (1)	BRPI0511135B8 (pl)
CA (1)	CA2564379C (pl)
DE (1)	DE102004024452A1 (pl)
DK (1)	DK1809293T3 (pl)
EA (1)	EA012583B1 (pl)
EC (1)	ECSP067004A (pl)
ES (1)	ES2575925T3 (pl)
HU (1)	HUE027780T2 (pl)
IL (1)	IL179218A (pl)
MX (1)	MXPA06013216A (pl)
MY (1)	MY148403A (pl)
NO (1)	NO20065030L (pl)
PE (1)	PE20060311A1 (pl)
PL (1)	PL1809293T3 (pl)
SG (1)	SG152265A1 (pl)
TW (1)	TWI356703B (pl)
UA (1)	UA87312C2 (pl)
UY (1)	UY28891A1 (pl)
WO (1)	WO2005110421A2 (pl)
ZA (1)	ZA200607462B (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7056916B2 (en)	2002-11-15	2006-06-06	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Medicaments for the treatment of chronic obstructive pulmonary disease
US7220742B2 (en)	2004-05-14	2007-05-22	Boehringer Ingelheim International Gmbh	Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
CN101208316B (zh)	2005-08-15	2012-05-09	贝林格尔·英格海姆国际有限公司	制备β-模拟物的方法
CA2627726A1 (en) *	2005-11-09	2007-05-18	Boehringer Ingelheim International Gmbh	Aerosolformulation for inhalation
UY30543A1 (es) *	2006-08-18	2008-03-31	Boehringer Ingelheim Int	Formulacion de aerosol para la inhalacion de beta- agonistas
US20110319402A1 (en) *	2008-11-21	2011-12-29	Boehringer Ingelheim International Gmbh	Aerosol formulation for the inhalation of beta agonists
US20110281858A1 (en) *	2008-11-21	2011-11-17	Boehringer Ingelheim International Gmbh	Aerosol formulation for the inhalation of beta agonists
WO2014056840A1 (en)	2012-10-09	2014-04-17	Boehringer Ingelheim International Gmbh	Beta-2-adrenoceptor agonist for the treatment of cough
JP2019536812A (ja)	2016-12-12	2019-12-19	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	オロダテロールとの同時投与による間質性肺疾患の処置方法に使用するためのニンテダニブ
JP2023504500A (ja) *	2019-12-05	2023-02-03	シンジェンタクロッププロテクションアクチェンゲゼルシャフト	フェニルエチルアミン誘導体の一段階調製方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3134590A1 (de) *	1981-09-01	1983-03-10	Boehringer Ingelheim KG, 6507 Ingelheim	Neue benzo-heterocyclen
US4460581A (en) *	1982-10-12	1984-07-17	Boehringer Ingelheim Kg	(1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones
JPH0637388B2 (ja) *	1986-02-17	1994-05-18	千寿製薬株式会社	水性液剤
GB9405019D0 (en) *	1994-03-15	1994-04-27	Smithkline Beecham Plc	Novel compounds
DE10253282A1 (de) *	2002-11-15	2004-05-27	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung
DE102004019539A1 (de) *	2004-04-22	2005-11-10	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Arzneimittel zur Behandlung von Atemwegserkrankungen
EA013157B1 (ru) *	2004-04-22	2010-02-26	Бёрингер Ингельхайм Интернациональ Гмбх	Содержащие бензоксазины лекарственные комбинации для лечения заболеваний дыхательных путей
DE102004024454A1 (de) *	2004-05-14	2005-12-08	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Enantiomerenreine Betaagonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE102004024451A1 (de) *	2004-05-14	2005-12-22	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Pulverformulierungen für die Inhalation, die Enantiomerenreine Betaagonisten enthalten

2004
- 2004-05-14 DE DE102004024452A patent/DE102004024452A1/de not_active Withdrawn
2005
- 2005-05-10 CN CNA2005800154865A patent/CN101056640A/zh active Pending
- 2005-05-10 EP EP05747843.0A patent/EP1809293B1/de not_active Expired - Lifetime
- 2005-05-10 HU HUE05747843A patent/HUE027780T2/en unknown
- 2005-05-10 EA EA200602017A patent/EA012583B1/ru not_active IP Right Cessation
- 2005-05-10 UA UAA200612949A patent/UA87312C2/ru unknown
- 2005-05-10 JP JP2007512068A patent/JP4620730B2/ja not_active Expired - Lifetime
- 2005-05-10 AU AU2005244414A patent/AU2005244414B2/en not_active Expired
- 2005-05-10 MX MXPA06013216A patent/MXPA06013216A/es active IP Right Grant
- 2005-05-10 BR BRPI0511135A patent/BRPI0511135B8/pt active IP Right Grant
- 2005-05-10 CA CA2564379A patent/CA2564379C/en not_active Expired - Lifetime
- 2005-05-10 KR KR1020067026225A patent/KR101288791B1/ko not_active Expired - Lifetime
- 2005-05-10 SG SG200902777-2A patent/SG152265A1/en unknown
- 2005-05-10 ES ES05747843.0T patent/ES2575925T3/es not_active Expired - Lifetime
- 2005-05-10 DK DK05747843.0T patent/DK1809293T3/en active
- 2005-05-10 PL PL05747843.0T patent/PL1809293T3/pl unknown
- 2005-05-10 WO PCT/EP2005/005028 patent/WO2005110421A2/de not_active Ceased
- 2005-05-11 UY UY28891A patent/UY28891A1/es not_active Application Discontinuation
- 2005-05-12 MY MYPI20052158A patent/MY148403A/en unknown
- 2005-05-12 PE PE2005000529A patent/PE20060311A1/es not_active Application Discontinuation
- 2005-05-13 AR ARP050101959A patent/AR049096A1/es unknown
- 2005-05-13 TW TW094115491A patent/TWI356703B/zh not_active IP Right Cessation
2006
- 2006-09-06 ZA ZA200607462A patent/ZA200607462B/en unknown
- 2006-11-02 NO NO20065030A patent/NO20065030L/no not_active Application Discontinuation
- 2006-11-13 IL IL179218A patent/IL179218A/en active IP Right Grant
- 2006-11-13 EC EC2006007004A patent/ECSP067004A/es unknown

Also Published As

Publication number	Publication date
BRPI0511135B8 (pt)	2021-05-25
JP2007537188A (ja)	2007-12-20
CA2564379C (en)	2013-07-30
ZA200607462B (en)	2008-06-25
ES2575925T3 (es)	2016-07-04
DE102004024452A1 (de)	2005-12-08
KR20070022084A (ko)	2007-02-23
KR101288791B1 (ko)	2013-07-29
AU2005244414A1 (en)	2005-11-24
WO2005110421A2 (de)	2005-11-24
AR049096A1 (es)	2006-06-28
AU2005244414B2 (en)	2010-12-09
ECSP067004A (es)	2007-02-28
BRPI0511135A (pt)	2007-11-27
PE20060311A1 (es)	2006-05-08
HUE027780T2 (en)	2016-11-28
JP4620730B2 (ja)	2011-01-26
NO20065030L (no)	2006-11-30
UA87312C2 (ru)	2009-07-10
CA2564379A1 (en)	2005-11-24
TW200608981A (en)	2006-03-16
BRPI0511135B1 (pt)	2019-11-12
SG152265A1 (en)	2009-05-29
TWI356703B (en)	2012-01-21
EA012583B1 (ru)	2009-10-30
IL179218A (en)	2012-10-31
CN101056640A (zh)	2007-10-17
IL179218A0 (en)	2007-03-08
EP1809293A2 (de)	2007-07-25
WO2005110421A3 (de)	2006-03-16
DK1809293T3 (en)	2016-06-20
EA200602017A1 (ru)	2007-06-29
EP1809293B1 (de)	2016-03-16
MXPA06013216A (es)	2007-02-08
MY148403A (en)	2013-04-30
UY28891A1 (es)	2005-12-30

Publication	Publication Date	Title
IL190682A0 (en)	2008-11-03	Aerosol formulation for the inhalation of beta agonists
IL197025A0 (en)	2009-11-18	Aerosol formulation for the inhalation of beta agonists
IL197024A0 (en)	2009-11-18	Aerosol formulation for the inhalation of beta agonists
ZA200804654B (en)	2014-07-30	Powder compositions for inhalation
IL174496A0 (en)	2006-08-01	Aerosol formulation for inhalation, containing an anticholinergic agent
EP1993646A4 (en)	2012-07-04	CONFIGURATION OF NOZZLE PORES FOR INTRA-PULMONARY ADMINISTRATION OF AEROSOL FORMULATIONS
ZA200903840B (en)	2010-03-31	Powder formulation for valganciclovir
GB0416328D0 (en)	2004-08-25	Use of dry powder compositions for pulmonary delivery
ZA200807486B (en)	2009-11-25	Medicament formulations comprising fluoroquinolones
IL183930A0 (en)	2007-10-31	Use of cladribine for preparation of pharmaceutical compositions
ZA200806929B (en)	2009-11-25	Nebulizer formulation
SG152265A1 (en)	2009-05-29	Aerosol formulation for inhalation of beta agonists
EP1806148A4 (en)	2009-12-02	THERAPEUTIC PREPARATION FOR INHALATION
DK1809236T3 (da)	2013-02-11	Pulverformuleringer til inhalation indeholdende enatiomeriske rene beta-agonister
PT1496876E (pt)	2008-04-15	Formulação de aerossol para a inalação contendo brometo de tiotrópio
ZA200900370B (en)	2010-01-27	Aerosol formulation for the inhalation of beta agonists
ATE401861T1 (de)	2008-08-15	Tiotropiumhaltige pulverformulierung für die inhalation
PL2094240T3 (pl)	2018-03-30	Stabilny preparat proszkowy zawierający środek antycholinergiczny
GB0501956D0 (en)	2005-03-09	Nebulizer formulation
PL2167042T3 (pl)	2016-02-29	Kompozycje farmaceutyczne w aerozolu zawierające flutykazon
ZA200900418B (en)	2009-11-25	Aerosol formulation for the inhalation of beta agonists
GB2451360B (en)	2011-10-05	Hormone replacement formulation
AP2006003734A0 (en)	2006-10-31	Inhalation formulation
ZA200606181B (en)	2007-10-31	Aerosol formulation
GB0519083D0 (en)	2005-10-26	Compositions for the improved delivery of medicaments